High CD21 Expression Affects Anti-CD19 Antibody Internalization and Efficacy
Author Information
Author(s): Ingle Gladys S, Chan Pamela, Elliott J Michael, Chang Wesley S, Koeppen Hartmut, Stephan Jean-Philippe, Scales Suzie J
Primary Institution: Genentech, Inc.
Hypothesis
CD21 expression inhibits the internalization of anti-CD19 antibodies, affecting their cytotoxicity.
Conclusion
High CD21 expression reduces the effectiveness of anti-CD19 antibody-drug conjugates in treating certain B-cell lymphomas.
Supporting Evidence
- High CD21 expression was found to correlate with reduced internalization of anti-CD19 antibodies.
- CD21-negative or low-expressing B-cell lines showed significantly better uptake of anti-CD19 antibodies.
- Clinical samples indicated that approximately 30% of diffuse large B-cell lymphoma patients lack CD21 expression.
Takeaway
If a type of cancer cell has a lot of CD21, it doesn't take in the medicine as well, making it harder to treat.
Methodology
The study examined the internalization of anti-CD19 and anti-CD21 antibodies in various B-cell lines and assessed their cytotoxic effects using antibody-drug conjugates.
Potential Biases
Potential bias due to the authors' affiliation with Genentech, Inc.
Limitations
The study primarily focused on in vitro models, which may not fully represent in vivo conditions.
Participant Demographics
The study included various B-cell lines and primary B-cells, with a focus on CD21 expression levels.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website